Idraparinux

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

WikiDoc Resources for Idraparinux
Articles
Most recent articles on Idraparinux Most cited articles on Idraparinux Review articles on Idraparinux Articles on Idraparinux in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Idraparinux Images of Idraparinux Photos of Idraparinux Podcasts & MP3s on Idraparinux Videos on Idraparinux
Evidence Based Medicine
Cochrane Collaboration on Idraparinux Bandolier on Idraparinux TRIP on Idraparinux
Clinical Trials
Ongoing Trials on Idraparinux at Clinical Trials.gov Trial results on Idraparinux Clinical Trials on Idraparinux at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Idraparinux NICE Guidance on Idraparinux NHS PRODIGY Guidance FDA on Idraparinux CDC on Idraparinux
Books
Books on Idraparinux
News
Idraparinux in the news Be alerted to news on Idraparinux News trends on Idraparinux
Commentary
Blogs on Idraparinux
Definitions
Definitions of Idraparinux
Patient Resources / Community
Patient resources on Idraparinux Discussion groups on Idraparinux Patient Handouts on Idraparinux Directions to Hospitals Treating Idraparinux Risk calculators and risk factors for Idraparinux
Healthcare Provider Resources
Symptoms of Idraparinux Causes & Risk Factors for Idraparinux Diagnostic studies for Idraparinux Treatment of Idraparinux
Continuing Medical Education (CME)
CME Programs on Idraparinux
International
Idraparinux en Espanol Idraparinux en Francais
Business
Idraparinux in the Marketplace Patents on Idraparinux
Experimental / Informatics
List of terms related to Idraparinux

Biotinylated Version of Idraparinux

Because idraparinux has a very long half life, a biotinylated version of this drug (SSR 126517) is also in clinical development. The addition of a biotin moiety to the structure allows the more rapid removal of the drug upon the addition of avidin. A bioequipotency study of biotinylated idraparinux vs. idraparinux for the treatment of DVT is ongoing.

Biotinylated idraparinux is being compared to warfarin for the treatment of pulmonary embolism in the phase III CASSIOPEA.

Reference

Template:WikiDoc Sources